Multilevel models provide a flexible modelling framework for cost-effectiveness analyses that use cluster randomised trial data. However, there is a lack of guidance on how to choose the most appropriate multilevel models. This paper illustrates an approach for deciding what level of model complexity is warranted; in particular how best to accommodate complex variance-covariance structures, rightskewed costs and missing data. Our proposed models differ according to whether or not they allow individual-level variances and correlations to differ across treatment arms or clusters and by the assumed cost distribution (Normal, Gamma, Inverse Gaussian). The models are fitted by Markov chain Monte Carlo methods. Our approach to model choice is based on four main criteria: the characteristics of the data, model pre-specification informed by the previous literature, diagnostic plots and assessment of model appropriateness. This is illustrated by re-analysing a previous cost-effectiveness analysis that uses data from a cluster randomised trial. We find that the most useful criterion for model choice was the deviance information criterion, which distinguishes amongst models with alternative variancecovariance structures, as well as between those with different cost distributions. This strategy for model choice can help cost-effectiveness analyses provide reliable inferences for policy-making when using cluster trials, including those with missing data.
Introduction
Policy-makers require cost-effectiveness analyses (CEAs) to help decide which health care programmes to prioritise. [1] [2] [3] [4] [5] For interventions that operate at a group level, CEAs commonly use data from cluster randomised trials (CRTs). A fundamental issue raised by the cluster design is that individuals within a cluster are likely to be more similar in their characteristics and the care they receive than those in different clusters. Methods that accommodate this clustering are well established for analysing clinical outcomes; however, a review of 62 published CEAs that used CRTs found that 37 (60%) adopted methods that disregarded clustering, which can not only underestimate statistical uncertainty, but also provide misleading point estimates. 6 CEAs provide evidence on the relative costs and health outcomes of alternative health care interventions. This requires studies to report the effects of alternative treatments on the joint distribution of costs and health outcomes, estimating the between-treatment differences in mean costs and health outcomes, together with their respective variances and covariances. 7 To meet this requirement, statistical methods for CEA that use data from cluster trials must address specific challenges. They must accommodate clustering in individuals' costs and health outcomes, but also recognise the correlation between these variables at both individual and cluster levels. [7] [8] [9] [10] Statistical methods are also required that make appropriate assumptions about the distribution of the outcome variables, recognising that costs tend to be heavily right-skewed. [11] [12] [13] The variance-covariance structure may be complex, i.e. individual-level costs may have variances, and correlations with health outcomes, that differ across clusters, for example because of clinical practice variations. 14 Missing data are a common problem, 15 and this needs to be handled in the analyses and acknowledged in the definition and calculation of measures of model fit. 16 Previous research has proposed alternative multilevel models (MLMs) for CEA and applied them to studies that use data from multicentre and cluster trials. 10, 14, 17, 18 However, within this framework many plausible MLMs can be specified and there is no guidance available on model choice.
This paper focuses on approaches for CEA that use data from cluster trials, assuming that any missing data are missing at random. Specifically, we propose and illustrate a set of criteria for choosing appropriate MLMs. The criteria proposed are visual inspection of the data, prespecifying models drawing on the previous literature, 13, 14, [19] [20] [21] diagnostic plots 22 and assessment of model appropriateness using the deviance information criterion (DIC). 23 We illustrate these criteria by performing a CEA using data from a CRT, introduced in the next section.
The outline for the remainder of the paper is as follows: In section 3, we introduce models drawing on the previous literature. In section 4, we apply these alternative models to our example; we present diagnostic plots, assessments of model appropriateness and CEA results. We conclude in section 5 with a discussion of the proposed strategy to model choice and suggest some areas for further research.
The Secondary Prevention of Heart disEase in geneRal practicE trial (SPHERE) study
The aim of the SPHERE study was to assess the effectiveness and cost-effectiveness of a secondary prevention strategy for patients with coronary heart disease. 24, 25 In SPHERE, 48 general practices (with 903 patients) were randomised to intervention (practices and patients had access to tailored care plans) or control (patients received usual care). The main endpoints were health service costs and health-related quality of life (HRQoL) assessed by administering the SF-12 questionnaire and recorded 18 months post-randomisation. Only 589 patients had complete endpoint data. HRQoL was converted into a utility measure using the SF-6D algorithm 26 and combined with mortality data to report quality-adjusted life years (QALYs) over 18 months. The CEA reported incremental QALYs, costs and the incremental net monetary benefit (INB), a measure of the relative value for money of alternative health care programmes. 27 The INB is calculated by estimating the difference between the treatment alternatives in the mean health outcomes, in this case QALYs, valuing this difference by the threshold willingness to pay for a unit of health gain (E20 000 per QALY in our illustrative analysis), and subtracting from this the incremental cost; so INB ¼ Áe -Ác, where Áe ¼ " e 1 À " e 0 , and Ác ¼ " c 1 À " c 0 are the incremental health outcomes and costs for treatment (subscript 1) versus control (subscript 0).
To help motivate the subsequent MLMs, incremental costs, QALYs and the INB are calculated with two contrasting approaches and reported in Table 1 . Firstly, we report 'individual-level' incremental effects by simply contrasting the means for all individuals within each randomised arm. This approach disregards clustering and assumes that each individual's endpoints are independent and have equal weight; and so the costs and outcomes for a cluster with many patients are given higher weight than those for a cluster with few patients. Secondly, we calculate the INB with the summary measures of mean costs and QALYs from each cluster. Under this approach, the mean endpoints in each cluster have the same weight irrespective of the numbers per cluster. For both approaches, we estimate the variance of the INB with a standard approach which assumes that the central limit theorem applies, and that variances and correlations between costs and outcomes are constant. 28 The alternative ways of weighting the data have little impact on the point estimates of the INB which are around E600 for each approach (Table 1) . By contrast, the Standard Error (SEs) of the INB are larger with the cluster summary approach versus the individual-level approach.
Rather than weighting the cluster means equally or according to the numbers per cluster, the subsequent MLMs weight the data in each cluster according to the amount of information within versus between clusters. The subsequent MLMs differ according to assumptions they make about whether or not the individual-level variances and covariances are assumed constant within clusters, and according to the assumed distribution of individual-level costs.
SPHERE illustrates several potential challenges for CEA that use CRT data, beyond the potential clustering of costs and health outcomes. Firstly, in pragmatic CRTs like SPHERE, the treatment protocols tend to accommodate clinical practice variations across clusters. Hence resource use and costs may have individual-level variances that differ across clusters. Secondly, individual costs and health outcomes tend to be correlated (for example, patients with lower health status may incur higher costs), and practice variations can result in individual-level correlations that differ across clusters (for example, some clusters might monitor patients with lower health status more intensively than others). Thirdly, costs tend to be heavily right-skewed; in SPHERE a small proportion of patients have lengthy hospital stays at high cost. Complexities, such as cost skewness and complex variation are present in CEA that use CRT more generally. 6 We now examine the features of the SPHERE data most relevant for the choice of MLM ( Figure 1 ; Table 1 ). The cost histograms show typically long right tails in both treatment arms ( Figure 1 ). We overlay three alternative distributions (Normal, Gamma and Inverse Gaussian) previously proposed for cost analysis 13, [19] [20] [21] [22] ; here the Inverse Gaussian appears to fit the cost data somewhat better. For QALYs, assuming Normality appears reasonable ( Figure 1 ).
The strength of clustering is commonly reported by the intra-cluster correlation coefficient (ICC) assuming constant within-cluster variation. When individual-level variances differ across clusters, the ICC can be uninformative, so we also report the I 2 statistic which was originally developed for measuring the degree of inconsistency in studies' results in a meta-analysis. 29 It is calculated as
Cochran's heterogeneity statistic and df the degrees of freedom, for example available from the metan command in Stata. 30 For each endpoint, I 2 describes the percentage of the total variability which is due to heterogeneity, in this case, differences in the means for each endpoint across clusters, rather than chance. 31 In SPHERE the I 2 is higher for costs (85%) than for QALYs (I 2 ¼ 52%). The standard deviations (SDs) for the individual-level QALYs were similar across treatment groups and clusters, but differed for the individual-level costs (Table 1; Figure 2 ) and tended to increase with mean costs per cluster (Levene's test of equal variances 32 across all clusters showed evidence of heterogeneity, p < 0.0001). The correlations between individual costs and QALYs appear to differ across clusters (range -0.7 to 0.8) but a forest plot of Fisher z-transformed correlations 33 suggests these differences are compatible with chance, and the heterogeneity across clusters is low (I 2 ¼ 0% for control and 27% for treatment clusters). These correlations were calculated using cases without missing endpoint data.
At the cluster level, the control group mean costs in SPHERE have a higher SD and more negative correlation with mean QALYs than the treatment group (Table 1) . However, SPHERE is typical of most CEA that use CRT data, in that there is limited information at the cluster level to assess whether parameters such as the cluster-level SD, or correlation between mean costs and mean QALYs, differ between treatment groups.
3 MLMs for the CEA SPHERE illustrates complexities that pervade CEA that use CRTs more generally, and these have implications for the choice of MLM. The mean costs but also the individual-level variances can be heterogeneous across clusters. 34 Costs and outcomes tend to be correlated at the individual-level and may differ by cluster. Cluster-level variances but also correlations between costs and health outcomes may differ by treatment group. Bivariate MLMs for CEAs that use CRTs have been previously proposed. 14, 35, 36 In the next stage of our proposed strategy, we pre-specify a series of MLMs that extend those previously considered 14, 35 by allowing individual-level correlations to vary across clusters, and cluster-level SDs and correlations to differ between treatment groups. We present a flexible modelling framework that recognises this complex variance-covariance structure, 14 accommodates highly skewed costs, and can be applied to CEAs with missing endpoint data.
MLMs for handling skewed costs
Cost data tend to be right skewed, and models that assume Normality can provide inefficient estimates of the mean cost. Any approach for addressing cost skewness has to recognise that the prime interest is in the treatment's effect on the population mean costs (and health outcomes). Therefore, if the costs are transformed (for example, by log-transformation), then results have to be back-transformed appropriately, which is not straightforward when there is heteroscedasticity. 22, 37, 38 While there is no consensus on which distributions should be considered for modelling health care costs, it is acknowledged that model specification is inherently complex, and the best parametric specification may well differ according to the specific dataset. 30 Our strategy for model choice is informed by recommendations from the literature which encourage the use of generalised linear models (GLMs), as they allow for non-Normal distributions, but directly report the effect of treatment on mean costs. 13, [19] [20] [21] [22] Specifically we consider costs to follow Gamma and Inverse Gaussian distributions which have variances proportional to increasing power of their means, i.e. 2 for Gamma and 3 for Inverse Gaussian, 39 and we examine their relative fit and appropriateness for the dataset in question.
There is evidence in SPHERE, and in CEA more generally, that the cost variance is not independent of the mean (Figure 2(a) ). In SPHERE, the variance for the QALYs does not appear to differ according to the mean in each cluster (Figure 2(b) ).
General structure of bivariate MLMs
Each of the following MLMs jointly models costs and health outcomes (e.g. QALYs), includes a linear additive treatment effect, and recognises potential heterogeneity in the mean costs and outcomes with cluster-specific random effects. The models considered differ by choice of cost distribution and according to the assumed variance-covariance structure. We let c ijk and e ijk represent costs and health outcomes for the ith individual in the jth cluster randomised to the kth treatment arm. Here j defines k as all individuals within a cluster receive the same randomised treatment, and for simplicity k takes the value 0 or 1 according to whether the cluster is randomised to the control or treatment group.
First we introduce, and assume throughout, bivariate Normal (BVN) cluster random effects u c j and u e j for cost and health outcomes, respectively
ek where variances 2 ck and 2 ek and correlation k may be specific to each treatment arm. We build the bivariate model on the expectations c ijk and e ijk of the two endpoints, c ijk and e ijk , following the bivariate models introduced by Nixon and Thompson 10, 13 for costs
and health outcomes, conditional on costs
The mean costs and health outcomes for the control group are represented by c 0 and e 0 , and the incremental costs and health outcomes of the randomised treatment by c 1 and e 1 , and the individual-level correlation is accommodated by the regression coefficient j .
Alternative cost distributions
Throughout, we assume that e ijk jc ijk $ Normalð e ijk , 2 ej Þ, while for c ijk we consider three possible distributions from the exponential family: Normal, Gamma and Inverse Gaussian (IG).
We begin by assuming that costs follow a Normal distribution, c ijk $ Normalð c ijk , 2 cj Þ and so, that individual-level residuals, " c ijk and " e ijk , are drawn from a BVN distribution with variances 2 cj and 2 ej and correlation j , all of which may differ across clusters. For these models, j ¼ j ej cj .
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where c ijk 4 0, s j 4 0 and c ijk > 0. The variance can then be written as c ijk =s j . So we write c ijk $ Gammað c ijk , s j Þ. Finally, the Inverse Gaussian distribution has been proposed for modelling highly skewed costs. 22, 40 We write c ijk $ IGð c ijk , s j Þ, parameterised by its mean () and shape (s) parameters, where > 0 and s > 0 (with consequent variance 3 /s).
Alternative variance-covariance matrices
The MLMs allow for different forms of complexity in the variance-covariance matrix. The differences across the MLMs are according to whether we allow for differences between randomised treatment groups and clusters in the individual-level variances (BVN models) or the corresponding shape parameter s j (Gamma and Inverse Gaussian models), and in the regression parameter between cost and health outcomes, j . The MLMs also differ in whether or not the cluster-level variances 2 ck and 2 ek and correlation k are allowed to differ by treatment group. The simplest bivariate Normal model (1) , assumes that all variances and correlations are constant across clusters, denoted by omitting the j and k subscripts from the variance-covariance matrices ( Table 2 ). Models 2a-c allow the individual-level variances to differ first by treatment (2a), then by cluster using either different fixed effects (FE) (2b) or random effects (RE) (2c). The FE specification assumes that the individual-level variances are different and independent from one another, whereas under REs the individual-level variances are assumed exchangeable, i.e. drawn from some common distribution. In many CRTs, there are some clusters with few patients and hence cluster-specific variance estimates can be imprecise. By using REs to model individual-level variances (and later correlations) we 'borrow strength' from the larger clusters to estimate the variances (and correlations) of the smaller clusters. 41 Models 3a-c allow individual-level correlations to differ first by treatment (3a), then by cluster using FEs (3b) or REs (3c). In Model 3c, the individual-level correlation, j , is transformed into z j using Fisher's z transformation 33 ; z j is modelled by REs with z j $ N( z , 2 z ). Models 4a-c extend models 3a-c in allowing cluster-level variances and correlations to differ by treatment group.
The analogous bivariate MLMs that assume costs follow a Gamma or Inverse Gaussian distribution allow the shape to differ either by treatment (k) or cluster (j). 13, 14 For these models, we specified constant variance for health outcome 2 ej , but allowed the regression parameter, j , to vary by treatment (k) or cluster (j).
Model implementation
We applied each of the BVN models described in Table 2 , and the analogous Gamma-Normal and Inverse Gaussian-Normal models to estimate incremental QALYs, costs and INBs in the SPHERE study. When fitting the models, we used rescaled costs (raw costs were divided by a value 4500). The mean (SD) of the scaled costs is 1.045 (1.209). The rescaling improved the stability of the Markov chain Monte Carlo (MCMC) estimation. Each model was fitted in WinBUGS by MCMC methods, 42 with three chains, each with a burn-in of 5000 iterations followed by 10,000 iterations. Posterior means are reported as 'point estimates'. Convergence was assessed by visual inspection of the mixing of the chains and the Gelman-Rubin statistics. 43 The Inverse Gaussian is not a standard distribution in WinBUGS, so we used a Bernoulli distribution with success rate i ¼ e l i , where l i is the Inverse Gaussian log-likelihood. 44 We assumed vague priors throughout. Wide Normal priors, N(0,10 6 ), were assumed for the mean QALYs, vague Gamma (0.01,0.01) for mean costs, wide Uniform priors for the log SDs of the individual QALYs and of the individual costs (BVN models), i.e. logð ej Þ $ U(-10,5) and logð cj Þ $U(-10,10) for costs. We also assumed wide uniform priors for the cluster-level SDs, i.e.
ek $ U(0,10) for QALYs, ck $ U(0,100) for costs 45 and U(-1,1) for the individual-level correlations j (BVN models), and throughout for the cluster-level correlations, k . In the models that used REs for modelling the individual-level SDs (i.e. 2c, 3c and 4c), we assumed logð ej Þ $ N( e , 2 e ) and logð cj Þ $ N( c , 2 c ); for these hyper-parameters we used N(0,10) priors for the means and U(0,10) for the SDs. For those models that used REs for individual-level Fisher's z transformed correlations (i.e. 3c and 4c), z j $ N( z , 2 z ), we used priors z $ N(0,10 6 ) and z $ U(0,1). For the Gamma-Normal models, we assumed wide Uniform priors, U(0,10), for the shape parameters, s j , and wide Normal N(0,10 6 ) for the regression parameters, j , when modelled by FEs. When modelled by REs we assumed log(s j ) $ N( s , 2 s ) with priors s $ N(0,10 4 ), s $ U(0,10); and j $ N( , 2 ) with priors $ N(0,10 6 ) and $ U(0,100). For the Inverse Gaussian-Normal models, the same priors were used for the regression and shape parameters but the shape was constrained to be >1.
Model comparison 4.1 Diagnostic plots
To inform the choice of distributions for the endpoints 33, 39 we considered normal plots of deviance residuals as a tool for assessing model fit. We used the posterior mean of the ijkth deviance residual as an estimate of the deviance residual for the corresponding individual.
The deviance residual Á t was defined as the signed square root of the individual contribution, d t , to the total deviance D.
, where y t is the observed, and t the expected value for individual t, so that P t Á 2 t ¼ D. With c ijk defined as in equation (1), the deviance residuals for the three distributions considered for costs, c ijk , are then given as
For models that fit the data well, the deviance residuals should approximate a Normal distribution and lie along the line of identity in the normal plots. 22 For each chosen cost distribution, the plots of the residual deviances do not reveal noticeable differences across the models with increasingly complex variance structure as shown by the three illustrative plots for each cost distribution in Figure 3 . However, when costs are assumed to follow a Gamma rather than a Normal distribution, the residual plots suggest some improvement in model fit; with further, albeit marginal gains when using an Inverse Gaussian distribution.
Model appropriateness
Overall model fit and appropriateness can be summarised by measures such as the mean deviance and the DIC. The advantage of the DIC is that it reflects predictive accuracy by penalising models which have a greater effective number of parameters, 23 and it is useful for comparing the fit of nonnested models. The DIC is calculated as DIC ¼ D( " ) þ 2p D , where D( " ) is the deviance evaluated at the posterior means of the parameters being estimated and p D is the effective number of parameters. The model with the lowest DIC may then be judged the 'most appropriate', although models with DIC within 5 units also warrant consideration. 46 Other related measures include the Akaike Information Criterion 47 and Bayesian Information Criterion, 48, 49 but both require the number of model parameters to be known which is problematic for random effects models.
The DIC is constructed using the likelihood of the parameters given the data and has been previously extended to the missing data setting. 16, 44, 50 Since in the SPHERE example some data are missing, we use the appropriate extension of the DIC, based on the observed data likelihood Lðhjy obs Þ, under ignorability of the missing data, 44 but conditional on the cluster. The inferential focus is the cluster, this being the DIC typically implemented for hierarchical models in WinBUGS. In the context of the missing data setting, we have DIC C ¼ Dðh, ujy obs Þ þ 2p D ¼ 2Dðh, ujy obs Þ À Dðh, ujy obs Þ ¼ À4Eflðh, ujy obs Þg þ 2lðh, ujy obs Þ where the cluster random effect u is considered as an extra parameter to be estimated, Dðh, ujy obs Þ ¼ À2E ½logf ðy obs ju, Þjy obs and p D denotes the number of effective parameters, defined as p D ¼ Dðh, ujy obs Þ À ðh, ujy obs Þ: This requires computation of the observed data likelihood for our bivariate models with random effects, which cannot be calculated automatically by WinBUGS. In particular, for those models assuming Gamma or Inverse Gaussaian distributions, the marginal distribution of the health outcomes does not have a known closed form, and we use Monte Carlo integration to calculate the corresponding likelihood and the DIC C . The intuitive reason for the need to calculate the DIC for a specific model using the observed data alone, rather than using the observed data and current Bayesian draw of the missing data, is that model fit should only be assessed with respect to the observed data. We report the DIC C , the deviance (at 
the posterior mean "
h, called the plug-in deviance) and the effective number of parameters across the MLMs under comparison.
As Table 3 shows, the MLMs that assumed an Inverse Gaussian distribution for individual costs gave substantially lower deviances and DICs, and were judged more appropriate than any of the bivariate Normal or Gamma-Normal models ( Table 3 ). Within each assumed cost distribution, the simplest MLM that assumed constant variances and correlations gave the highest DIC; moving to MLMs with more complex variance-covariance structures generally improved model fit and appropriateness; these gains were relatively large for the bivariate Normal models ( Table 3 ). The two models with the lowest DIC were the Inverse Gaussian-Normal models that allowed individuallevel shape and regression parameters to differ by cluster using REs (Models 3c and 4c).
Analogous models (3b and 4b) that allowed the shape and regression parameters to differ by fixed effects gave lower residual deviances, but these models required many more parameters to be fitted and hence resulted in higher DICs.
Cost-effectiveness results
The cost-effectiveness results across all the models considered reported that the intervention had positive point estimates of the INB, with 95% credible intervals that included zero (Figure 4 ). For the Inverse Gaussian-Normal models, the point estimates (95% credible intervals) were similar across the MLMs with different variance-covariance matrices (Figure 4 ). Within the alternative bivariate Normal models, there were more differences in both the point estimates and width of the credible intervals versus the more appropriate Gamma-Normal and Inverse Gaussian-Normal models. In particular, the bivariate Normal models 2b-c and 3b-c gave much narrower credible intervals than their better fitting Inverse Gaussian and Gamma counterparts (Figure 4 ). The two Inverse Gaussian-Normal models with the lowest DIC (models 3c and 4c) gave similar INBs of around E600 (95% credible intervals from around -500 to 1600). Some of the Inverse Gaussian-Normal models, which considered a simpler variance-covariance structure gave a somewhat Table 3 . Model fit and appropriateness (deviances a at posterior parameter means, effective numbers of parameters and DICs c ).
Model
Bivariate Normal Gamma-Normal Inverse Gaussian-Normal The DICs in bold correspond to the smallest, and therefore represent best fit for the data amongst the models considered here. different INB; for example, the simplest Inverse Gaussian-Normal model (1) reported an INB of approximately E400 (95% credible interval from -1200 to 1800).
Discussion
This paper extends previous research on statistical methods for CEA 7, 10, 14, 35, 36 by providing an approach for choosing amongst MLMs for CEA that use cluster trials. Such studies tend to have complex data structures, and current CEA methods do not offer advice for choosing amongst a range of models. 14 This paper encourages future studies to take a systematic approach to model choice in considering a range of alternative model specifications to address issues such as missing data, cost skewness and between-cluster differences in the variances of individual costs. Our paper therefore addresses an important gap in the literature by providing a strategy for model choice with four complementary strands: (a) data description, (b) pre-specification of MLMs drawing on the literature, (c) diagnostic plots and (d) assessment of model fit and appropriateness, where there are missing data. To help future CEAs that use cluster trial data choose between MLMs, we provide sample WinBUGS code for calculating the DIC when some cost or health outcome data are missing, together with code for estimating bivariate models that can handle right-skewed costs and complex variance structures (for example, Inverse Gaussian-Normal, model 4c see http://www.lshtm.ac.uk/ php/departmentofhealthservicesresearchandpolicy/ceathatuseclustertrials/researchoutput/f.txt).
Our approach to model choice was illustrated by re-analysis of a CRT, which is representative of the challenges faced by CEAs in these settings. 6 In particular, the cost data were rightskewed, and clinical practice variations appeared to lead to individual cost variances that differed across clusters. In these circumstances, many alternative MLMs warrant consideration and can be fitted by MCMC in WinBUGS, or in OpenBUGs which has now implemented the Inverse Gaussian distribution. 51 The data description encouraged the specification of MLMs that allowed individual costs to have non-Normal distributions with variances that differed by cluster, but assumed that health outcomes were Normally distributed. SPHERE, like many CRTs, 6 has moderate numbers of clusters and so little information was available on cluster-level parameters such as the correlation between mean costs and health outcomes. Hence, a careful description of the salient features of the data appears a necessary but insufficient criterion for model choice.
We followed recommendations for handling right-skewed cost data, and considered the GLM family of models, such as those that assume a Gamma or Inverse Gaussian distribution. 22 These can accommodate common mean-variance relationships, but allow the choice of a range of link and variance functions. While in our example, it was plausible to assume that treatment had an additive effect on mean costs and health outcomes, if a priori reasoning and the data description suggest treatment has a multiplicative effect, then a GLM with a log-link could be chosen instead. 18 In principle the proposed approach, of using residual plots and a measure of model appropriateness such as the DIC, can also inform the choice of link function.
In the SPHERE study, we found that plots of individual-level residuals can help in choosing amongst MLMs that make different distributional assumptions: the MLMs that assumed costs were from Inverse Gaussian distributions appeared to fit the data relatively well. However, these residual plots were less useful for differentiating between models with different variance-covariance matrices. Alternative diagnostic tools such as Bayesian p-values could also be considered, but they require simulations from the posterior distribution which is not straightforward for distributions beyond those available by default in the modelling software WinBUGS.
Of the criteria considered, we found that the DIC was the most useful overall for choosing amongst the plausible MLMs; it differentiated between cost distributions but also amongst models with alternative variance-covariance structures. Other ways of comparing models include Bayes factors 52 and cross-validation. 53, 54 In line with standard practice in WinBUGS, the DIC we have reported here is calculated conditional on the cluster random effects. Marginalising over these (except for the tractable BVN models) involves computationally intensive double numerical integration which is beyond the scope of this paper. Our approach to model choice is not intended to lead the analyst to a single MLM. Indeed in the SPHERE study, at least two models warranted careful consideration (Inverse Gaussian-Normal models 3c and 4c). While in this example, plausible models yielded similar cost-effectiveness estimates, more generally in CEA, models with similar fit may result in radically different inferences. 13 A formal and objective way to synthesise the results from alternative models, while accounting for the uncertainty around model choice, is to employ Bayesian model averaging. 55 In CEA, previous methodological studies have encouraged analysts to fit models by MCMC estimation, in WinBUGS, because this offers a wide choice of distributions. 10, 14, 56 This raises the potential concern that results can be sensitive to the choice of prior distributions particularly for cluster-level parameters such as the random effects. 57 For all model parameters, we aimed to choose vague prior distributions. However, there is no universally accepted standard for vague priors, and analysts are encouraged to explore the sensitivity of results to alternative choices of prior distributions. 58 In the SPHERE example, we found that the estimates of the INB were very similar when we chose alternative prior distributions. This paper has some limitations. Firstly, the residual plots suggested there was scope for improvement in the fit of the models to the cost data. Secondly, the approach presented was illustrated for a single dataset. Other CEAs of CRTs may present further challenges; for example they may require covariate adjustment, health outcomes may be binary rather than continuous and may take the form of repeated measures over time. Thirdly, in common with previous studies the approach did not consider whether it was plausible to assume that cluster-level residuals were Normally distributed. 14, 35 In CEA, the major interest is in the incremental cost-effectiveness, and such fixed parameter estimates have been shown to be generally robust to misspecification of the distribution of random effects. 59 Nonetheless, our models could be expanded to consider non-Normal distributions for the random effects.
The approach presented to model choice for CEA that use CRT data opens up areas for further research. Firstly, the approach to model choice could consider a broader range of alternatives for handling skewed costs. These include flexible parametric approaches such as beta-type size distributions that can model cost skewness and heterogeneity as a function of covariates, 60 and common alternatives to the GLMs considered, such as the lognormal distribution. Secondly, this paper focuses on CEA that use data from cluster trials, but approaches to model choice are also required for other study designs such as CEA that use multicentre or multinational Randomised Controlled Trial. 17, 18 Thirdly, the proposed approach to model choice could be expanded to the context where data are assumed missing not at random. Here, the use and interpretation of measures of model appropriateness such as DIC raise challenges which are currently unresolved. 50 
